Botulinum neurotoxin treatment in children with cerebral palsy: A population-based study in Norway

Himmelmann, 2007, Bilateral spastic cerebral palsy – prevalence through four decades, motor function and growth, Eur J Paediat Neurol, 11, 215, 10.1016/j.ejpn.2006.12.010 Ronan, 2007, Nonoperative management of spasticity in children, Child’s Nervous System, 23, 943, 10.1007/s00381-007-0396-4 Andersen, 2008, Cerebral palsy in Norway: prevalence, subtypes and severity, Eur J Paediat Neurol, 12, 4, 10.1016/j.ejpn.2007.05.001 Dunne, 1995, Treatment of chronic limb spasticity with botulinum toxin A, J Neurol Neurosurg Psychiatr, 58, 232, 10.1136/jnnp.58.2.232 Bell, 2002, Natural progression of gait in children with cerebral palsy, J Pediatr Orthop, 22, 677, 10.1097/00004694-200209000-00020 Gough, 2004, Short-term outcome of multilevel surgical intervention in spastic diplegic cerebral palsy compared with the natural history, Dev Med Child Neurol, 46, 91, 10.1111/j.1469-8749.2004.tb00457.x Johnson, 1997, The evolution of gait in childhood and adolescent cerebral palsy, J Pediatr Orthop, 17, 392, 10.1097/00004694-199705000-00022 Simpson, 2004, Identification of the major steps in botulinum toxin action, Annu Rev Pharmacol Toxicol, 44, 167, 10.1146/annurev.pharmtox.44.101802.121554 Koman, 1993, Management of cerebral palsy with botulinum-A toxin: preliminary investigation, J Pediatr Orthop, 13, 489, 10.1097/01241398-199307000-00013 Naumann, 2006, Safety and efficacy of botulinum toxin type A following long-term use, Eur J Neurol, 13, 35, 10.1111/j.1468-1331.2006.01652.x Delgado, 2010, Neurology, 74, 336, 10.1212/WNL.0b013e3181cbcd2f Naidu, 2010, Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy, Dev Med Child Neurol, 52, 139, 10.1111/j.1469-8749.2009.03583.x Koman, 2000, Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group, J Pediatr Orthop, 20, 108, 10.1097/00004694-200001000-00022 Scholtes, 2006, The combined effect of lower-limb multilevel botulinum toxin type A and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial, Arch Phys Med Rehabil, 87, 1551, 10.1016/j.apmr.2006.08.342 Sutherland, 1999, Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy, Gait Posture, 10, 1, 10.1016/S0966-6362(99)00012-0 Ubhi, 2000, Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy, Arch Dis Child, 83, 481, 10.1136/adc.83.6.481 Bjornson, 2007, Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation, Pediatrics, 120, 49, 10.1542/peds.2007-0016 Pandyan, 2001, Biomechanical examination of a commonly used measure of spasticity, Clin Biomech (Bristol, Avon), 16, 859, 10.1016/S0268-0033(01)00084-5 Love, 2010, Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement, Eur J Neurol, 17, 9, 10.1111/j.1468-1331.2010.03126.x Heinen, 2010, The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy, Eur J Paediatr Neurol, 14, 45, 10.1016/j.ejpn.2009.09.005 Cans, 2000, Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers, Dev Med Child Neurol, 42, 816, 10.1111/j.1469-8749.2000.tb00695.x Rosenbaum, 2008, Development of the gross motor function classification system for cerebral palsy, Dev Med Child Neurol, 50, 249, 10.1111/j.1469-8749.2008.02045.x Palisano, 1997, Development and reliability of a system to classify gross motor function in children with cerebral palsy, Dev Med Child Neurol, 39, 214, 10.1111/j.1469-8749.1997.tb07414.x Beckung, 2002, Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy, Dev Med Child Neurol, 44, 309, 10.1111/j.1469-8749.2002.tb00816.x Eliasson, 2006, The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability, Dev Med Child Neurol, 48, 549, 10.1017/S0012162206001162 Simpson, 2008, Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology, 70, 1691, 10.1212/01.wnl.0000311391.00944.c4 Wasiak, 2004, Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy, Cochrane Database Syst Rev, 4, CD003469 Berweck, 2004, Sonography-guided injection of botulinum toxin in children with cerebral palsy, Lancet, 363, 249, 10.1016/S0140-6736(03)15351-2 Berweck, 2002, Sonography-guided injection of botulinum toxin A in children with cerebral palsy, Neuropediatrics, 33, 221, 10.1055/s-2002-34500 Westhoff, 2003, Ultrasound-guided botulinum toxin injection technique for the iliopsoas muscle, Dev Med Child Neurol, 45, 829, 10.1111/j.1469-8749.2003.tb00898.x Yang, 2009, Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography, Arch Phys Med Rehabil, 90, 741, 10.1016/j.apmr.2008.10.025 Py, 2009, Evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance, Ann Phys Rehabil Med, 52, 215, 10.1016/j.rehab.2009.02.005 Kwon, 2010, Botulinum toxin a injection into calf muscles for treatment of spastic equinus in cerebral palsy: a controlled trial comparing sonography and electric stimulation-guided injection techniques: a preliminary report, Am J Phys Med Rehabil, 89, 279, 10.1097/PHM.0b013e3181ca24ac Preston, 2011, J Rehabil Med, 43, 1010, 10.2340/16501977-0893 Satila, 2010, Botulinum toxin type A injections for treatment of spastic equinus in cerebral palsy: a secondary analysis of factors predictive of favorable response, Am J Phys Med Rehabil, 89, 865, 10.1097/PHM.0b013e3181f1c5e7